Format

Send to

Choose Destination
Oncology. 2018;94(4):215-222. doi: 10.1159/000486483. Epub 2018 Feb 9.

Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.

Author information

1
Department of Medicine and Molecular Science, Division of Frontier Medical Science, Hiroshima University, Hiroshima, Japan.
2
Hiroshima City Asa Hospital, Hiroshima, Japan.
3
Hiroshima Red Cross Hospital, Hiroshima, Japan.
4
Kure Medical Center, Hiroshima, Japan.
5
Chugoku Rousai Hospital, Hiroshima, Japan.
6
Hiroshima General Hospital, Hiroshima, Japan.
7
Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan.

Abstract

OBJECTIVE:

To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT).

METHODS:

This retrospective study included 108 HCC patients with PVTT of the main trunk or first branch and Child-Pugh ≤7. Sixty-eight received HAIC + RT and 40 received sorafenib. Patients were then assigned to the HAIC + RT group (n = 36) and the sorafenib group (n = 36) through case-control matching. The decision to treat with HAIC + RT or sorafenib was left to the attending physician.

RESULTS:

The median overall, progression-free, and postprogression survival were significantly longer in the HAIC + RT group than in the sorafenib group (9.9 vs. 5.3, p = 0.002; 3.9 vs. 2.1, p = 0.048; and 3.7 vs. 1.9 months, p = 0.02, respectively). Multivariate analysis identified HAIC + RT (hazard ratio = 2.02; 95% confidence interval, 1.14-3.57; p = 0.01) as a significant and independent determinant of overall survival.

CONCLUSIONS:

In patients with advanced HCC and major PVTT, survival was significantly longer in those treated with HAIC + RT than with sorafenib.

KEYWORDS:

Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Radiotherapy; Sorafenib

PMID:
29428943
DOI:
10.1159/000486483
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center